Formulation and Evaluation of Famotidine Floating Matrix Tablets - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Formulation and Evaluation of Famotidine Floating Matrix Tablets
The authors investigated the effects of formulation and processing parameters on floating matrix-controlled drug-delivery systems.

Pharmaceutical Technology
Volume 33, Issue 10, pp. 60-70


Table II: Evaluation parameter of tablets of all batches.
Tablets preparation. Different tablet formulations of 100 tablets each were prepared using direct compression. All powders were passed though an 80-mesh sieve. The required quantity of drug, matrix polymer (natural and synthetic), and low-density powder were mixed thoroughly. Talc and magnesium stearate were added as a glidant and a lubricant, respectively. Blending was carried out using a laboratory-scale V-blender with a 100-g capacity (modelAP-01, Orchid Scientifics, Nashik, Maharashtra, India) for 30 min. The blend was compressed with a multipunch tablet compressor (lab press, Cadmach Csi 670, India) at dwell times of 20 s and under a pressure of 25 kg/cm2 . Each tablet contained 40 mg of famotidine and other pharmaceutical ingredients (see Table I). The tablets were round and flat with an average diameter of 8.0 0.1 mm, a hardness of 4–6 kg/cm2 , and a thickness of 4.0 0.2 mm. The tablets were evaluated for weight variation, drug content, and floating lag time (see Table II).

Floating behavior. In vitro buoyancy was determined by determining the floating lag time (i.e., the time period between placing the tablet in the medium and the tablet floating) (15). The tablets were placed in a 100-mL beaker containing 0.1 N HCl. The time required for the tablets to rise to the surface and float was defined as the floating lag time.

In vitro dissolution studies. The release rate of famotidine from the floating tablets (n = 3) was determined using United State Pharmacopoeia (USP) XXIV dissolution testing apparatus II (paddle method). The dissolution test was performed using 900 mL of 0.1 N HCl at 37 0.5C and 50 rpm. A 10-mL sample of the solution was withdrawn from the dissolution apparatus hourly for 8 h, and the samples were replaced with fresh dissolution medium. The samples were filtered through a 45-m membrane filter and diluted to a suitable concentration with 0.1N HCl. Absorbance of these solutions was measured at 265 nm using a Shimadzu (Kyoto, Japan) UV-1601 UV–vis double-beam spectrophotometer. Cumulative percentage of drug release was calculated using an equation obtained from a standard curve.

Comparison of dissolution profiles. The similarity factor (f 2 ) given by scale-up and postapproval changes (SUPAC) guidelines for modified-release dosage forms was used as a basis to compare dissolution profiles. The dissolution profiles are considered similar when f 2 is between 50 and 100 (16).


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here